Compare Gilead Sciences, Inc. (GILD) vs Hormel Foods Corp (HRL) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Gilead Sciences, Inc. vs Hormel Foods Corp — how do they compare? Gilead Sciences, Inc. trades at $133.5 (market cap $163.51B), while Hormel Foods Corp trades at $25.78 (market cap $13.84B). The key difference: Gilead Sciences, Inc. is far larger — about 11.8× Hormel Foods Corp's market cap, and Hormel Foods Corp pays the higher dividend (4.65%). Which is the better fit depends on your goals.
| GILD | HRL | |
|---|---|---|
Market Cap | $163.51B | $13.84B |
Sector | Health | Consumer Staples |
52-Week High | $155.80 | $29.91 |
52-Week Low | $108.22 | $19.74 |
Enterprise Value | $178.05B | $15.84B |
Dividend Yield | 2.49% | 4.65% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Gilead Sciences (GILD) trades at $133.30, up 2.51% today, with strong technical momentum above key support at $130. The company demonstrates robust fundamentals with a 30.99% net income margin and consistent earnings beats in recent quarters. Recent FDA and EC approvals for Trodelvy in metastatic triple-negative breast cancer highlight growth potential beyond its HIV franchise.
Outlook remains positive with a consensus price target of $152.83 offering 14.6% upside, though risks include patent expirations and competitive pressures. The stock presents a compelling opportunity driven by oncology expansion and strong cash flow generation, supported by overwhelming analyst bullish sentiment.
Hormel Foods (HRL) trades at $24.80, up 1.39% on the day, with a bullish technical signal from moving averages and recent earnings beats. The stock shows a P/E of 29.59 and net margin of 3.82%, while analyst consensus is mixed with a $26.33 price target. Recent business moves include selling its Brazilian Ceratti operations to streamline international focus, as reported by PRNewsWire on June 29, 2026.
The outlook presents a stable dividend play with 60 consecutive years of increases, but risks include margin pressure and competitive headwinds. Upside is supported by valuation near multi-year lows and consistent cash flow, while downside stems from modest growth and profit margin compression observed in 2025 financials.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Gilead Sciences, Inc.
Gilead Sciences develops and markets therapies to treat life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. The acquisitions of Corus Pharma, Myogen, CV Therapeutics, Arresto Biosciences, and Calistoga have broadened this focus to include pulmonary and cardiovascular diseases and cancer. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of combination drug Harvoni, and the Kite, Forty Seven, and Immunomedics acquisitions boost Gilead's exposure to cell therapy and noncell therapy in oncology.
Read more on GILD →About Hormel Foods Corp
Hormel Foods is a protein-focused branded food company. Its brands include its namesake Hormel, Spam, Jennie-O, Dinty Moore, Applegate, Wholly Guacamole, and Skippy. The vast majority of the company's revenue is U.S.-based: 64% U.S. retail, 28% U.S. food service, and 8% international. By product type, in fiscal 2021, 23% of revenue was shelf-stable foods, 18% was poultry (branded and commodity), 55% was other perishable food, and 3% was other, primarily nutritional products. The company holds the number-one market position in shelf-stable meat, shelf-stable ready meals, pepperoni, natural/organic deli meat, and guacamole and the number-two position in turkey, bacon, chilled ready meals, and peanut butter.
Read more on HRL →
